One in four patients requiring hemodialysis will die from access failure.
At Ariste, we are developing a new class of drug eluting devices that will offer improved performance over legacy products. Our technology will help prevent device failure, resulting in improved patient outcomes and saving money for both hospitals and Medicare.
Surgical infection continues to cause unnecessary morbidity and mortality.
At Ariste, we are developing a new class of drug eluting devices that will offer improved performance over legacy products. Our technology will help prevent device failure, resulting in improved patient outcomes and saving money for both hospitals and Medicare.
Restenosis is a common cause of device failure.
At Ariste, we are developing a new class of drug eluting devices that will offer improved performance over legacy products. Our technology will help prevent device failure, resulting in improved patient outcomes and saving money for both hospitals and Medicare.